Calliditas Therapeutics Unveils Promising Insights at the 62nd European Renal Association Congress

Calliditas Therapeutics Showcases New Data at the 62nd European Renal Association Congress

Calliditas Therapeutics, a part of Asahi Kasei Corporation, made headlines with its recent presentation of groundbreaking data at the 62nd European Renal Association Congress (ERA Congress), held in Vienna, Austria from June 4 to 7, 2025. This prestigious event served as a platform for discussing advancements in kidney health and renal science.

The company unveiled secondary analyses and novel insights derived from biomarkers associated with its Phase 3 NefIgArd study, which focuses on its product Nefecon (marketed as TARPEYO® in the United States). TARPEYO® is specifically designed for patients suffering from primary immunoglobulin A nephropathy (IgAN)—a condition that can lead to progressive kidney damage.

During the congress, a total of five abstracts from Calliditas were accepted for presentation. Notably, one of these was recognized as a Top 10 abstract, highlighting its significance within the scientific community. The presentations not only emphasized the importance of Nefecon in treating IgAN but also showcased the innovative research being conducted by Calliditas in a field that faces significant challenges.